A biopharmaceutical company established to combine cannabinoid medicine with world class scientific research.

Oxford Cannabinoid Technologies are aiming to become a global leader in the development of safe and effective prescription medicines for chronic pain conditions.

Safe and Effective

Trials have shown that medicinal cannabinoids are non-addictive, non-psychotropic and have no known serious side effects.

Trialled

OCTP have partnered with Oxford University, using their renowned clinical trial facilities to develop medicinal cannabinoids as an alternative to opioids.

Oxford Partnership
Expansion

Oxford Cannabinoids are constantly looking to expand their pipeline, whether that be in-licensing compounds or outsourcing our assets to optimise application in different therapeutic areas

Targeting Pain Market

OCTP are targeting the global pain market which is estimated to reach £42.5bn.



A biopharmaceutical company established to combine cannabinoid medicine with world class scientific research.

Oxford Cannabinoid Technologies are aiming to become a global leader in the development of safe and effective prescription medicines for chronic pain conditions.

Safe and Effective

Trials have shown that medicinal cannabinoids are non-addictive, non-psychotropic and have no known serious side effects.

Trialled

OCTP have partnered with Oxford University, using their renowned clinical trial facilities to develop medicinal cannabinoids as an alternative to opioids.

Oxford Partnership
Expansion

Oxford Cannabinoids are constantly looking to expand their pipeline, whether that be in-licensing compounds or outsourcing our assets to optimise application in different therapeutic areas

Targeting Pain Market

OCTP are targeting the global pain market which is estimated to reach £42.5bn.

A biopharmaceutical company established to combine cannabinoid medicine with world class scientific research.

Oxford Cannabinoid Technologies are aiming to become a global leader in the development of safe and effective prescription medicines for chronic pain conditions.

Safe and Effective

Trials have shown that medicinal cannabinoids are non-addictive, non-psychotropic and have no known serious side effects.

Trialled

OCTP have partnered with Oxford University, using their renowned clinical trial facilities to develop medicinal cannabinoids as an alternative to opioids.

Oxford Partnership
Expansion

Oxford Cannabinoids are constantly looking to expand their pipeline, whether that be in-licensing compounds or outsourcing our assets to optimise application in different therapeutic areas

Targeting Pain Market

OCTP are targeting the global pain market which is estimated to reach £42.5bn.

A biopharmaceutical company established to combine cannabinoid medicine with world class scientific research.

Oxford Cannabinoid Technologies are aiming to become a global leader in the development of safe and effective prescription medicines for chronic pain conditions.

Safe and Effective

Trials have shown that medicinal cannabinoids are non-addictive, non-psychotropic and have no known serious side effects.

Trialled

OCTP have partnered with Oxford University, using their renowned clinical trial facilities to develop medicinal cannabinoids as an alternative to opioids.

Oxford Partnership
Expansion

Oxford Cannabinoids are constantly looking to expand their pipeline, whether that be in-licensing compounds or outsourcing our assets to optimise application in different therapeutic areas

Targeting Pain Market

OCTP are targeting the global pain market which is estimated to reach £42.5bn.



A biopharmaceutical company established to combine cannabinoid medicine with world class scientific research.

Oxford Cannabinoid Technologies are aiming to become a global leader in the development of safe and effective prescription medicines for chronic pain conditions.

Safe and Effective

OCTP have partnered with Oxford University, using their renowned clinical trial facilities to develop medicinal cannabinoids as an alternative to opioids.

Oxford Partnership
Expansion

Oxford Cannabinoids are constantly looking to expand their pipeline, whether that be in-licensing compounds or outsourcing our assets to optimise application in different therapeutic areas

Targeting Pain Market

OCTP are targeting the global pain market which is estimated to reach £42.5bn.

Trials have shown that medicinal cannabinoids are non-addictive, non-psychotropic and have no known serious side effects.

Trialled

A biopharmaceutical company established to combine cannabinoid medicine with world class scientific research.

In line with compliance regulations, SatoshiPay aims to enable access to advanced payment infrastructure with as little as an email address and payment wallet.

Inclusive

OCTP have partnered with Oxford University, using their renowned clinical trial facilities to develop medicinal cannabinoids as an alternative to opioids.

Oxford Partnership

Trials have shown that medicinal cannabinoids are non-addictive, non-psychotropic and have no known serious side effects.

Trialled
Targeting Pain Market

OCTP are targeting the global pain market which is estimated to reach £42.5bn.

Oxford Cannabinoid Technologies are aiming to become a global leader in the development of safe and effective prescription medicines for chronic pain conditions.

Safe and Effective